Search results
Showing 631 to 645 of 2580 results for methods
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
In development Reference number: GID-TA11336 Expected publication date: TBC
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
In development Reference number: GID-TA11501 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.
Artificial intelligence software to help detect and characterise colorectal polyps
In development Reference number: GID-DG10118 Expected publication date: TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
In development Reference number: GID-TA11630 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.